JPMorgan Chase & Co. Has $395,000 Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX)

JPMorgan Chase & Co. grew its stake in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 512.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 272,328 shares of the company's stock after acquiring an additional 227,864 shares during the period. JPMorgan Chase & Co. owned about 0.20% of Compass Therapeutics worth $395,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Intech Investment Management LLC grew its holdings in Compass Therapeutics by 218.7% in the fourth quarter. Intech Investment Management LLC now owns 51,924 shares of the company's stock valued at $75,000 after purchasing an additional 35,632 shares during the last quarter. Sequoia Financial Advisors LLC acquired a new stake in Compass Therapeutics in the 4th quarter valued at about $45,000. Independent Advisor Alliance acquired a new position in Compass Therapeutics during the fourth quarter worth about $26,000. Bank of New York Mellon Corp lifted its holdings in shares of Compass Therapeutics by 2.6% in the fourth quarter. Bank of New York Mellon Corp now owns 237,975 shares of the company's stock valued at $345,000 after purchasing an additional 6,041 shares in the last quarter. Finally, Rhumbline Advisers grew its position in shares of Compass Therapeutics by 3.1% in the fourth quarter. Rhumbline Advisers now owns 129,116 shares of the company's stock valued at $187,000 after purchasing an additional 3,822 shares during the last quarter. Institutional investors and hedge funds own 68.43% of the company's stock.

Compass Therapeutics Stock Performance

Shares of Compass Therapeutics stock traded up $0.07 during trading on Wednesday, reaching $1.76. The company's stock had a trading volume of 1,503,616 shares, compared to its average volume of 892,145. The business's fifty day moving average price is $2.03 and its 200-day moving average price is $2.09. Compass Therapeutics, Inc. has a one year low of $0.77 and a one year high of $4.08. The firm has a market cap of $243.38 million, a price-to-earnings ratio of -4.76 and a beta of 1.40.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Sell-side analysts anticipate that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.

Insider Buying and Selling at Compass Therapeutics

In other Compass Therapeutics news, insider Jonathan Anderman acquired 20,000 shares of the business's stock in a transaction dated Monday, April 7th. The stock was bought at an average cost of $1.54 per share, with a total value of $30,800.00. Following the completion of the transaction, the insider now directly owns 21,000 shares in the company, valued at approximately $32,340. This represents a 2,000.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Carl L. Gordon sold 3,571,428 shares of the business's stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The disclosure for this sale can be found here. Corporate insiders own 28.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on CMPX. HC Wainwright reaffirmed a "buy" rating and issued a $24.00 target price on shares of Compass Therapeutics in a research note on Monday, April 21st. Wedbush reiterated an "outperform" rating and set a $8.00 price objective on shares of Compass Therapeutics in a research report on Tuesday, April 1st. Leerink Partnrs raised shares of Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 1st. Jefferies Financial Group raised their price objective on Compass Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a report on Monday, February 10th. Finally, Piper Sandler began coverage on shares of Compass Therapeutics in a report on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 target price for the company. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Compass Therapeutics currently has an average rating of "Buy" and an average target price of $13.38.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.